News
Imricor is the global leader in the development and manufacture of MRI compatible devices for performing cardiac ablations. A cardiac ablation is a procedure conducted by an electrophysiologist where a catheter is guided into the heart with the purpose of burning/ablating the tissue responsible for causing the arrythmia (irregular heartbeat).
The cardiac ablation market, which is over US$8bn per year, currently uses X-Ray guidance to identify the location in the heart that requires treatment. X-Ray as an imaging tool has limitations as it does not show the soft tissue of the heart and exposes the patients and physicians to repeated radiation.
Imricor has the only cardiac ablation devices in the world that have been proven to be safe and effective inside the magnetic field generated by an MRI and, after 18 years of research and development, is now commercialising globally with approvals in Europe, the Middle East and soon to be in both Australia (2024) and the US (2025). The technology is protected by over 70 global patents.
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
Market highlights and ASX small caps to watch on Wednesday
News
Last Orders: What you might have missed on the ASX today
News
Rise and Shine: What you need to know before the ASX opens
News
Last Orders: What you might have missed on the ASX today
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Imricor gets distribution boost in Europe with new Philips deal
Health & Biotech
Check up: Health stocks firing on excitement… and little else
Escrow Watch
Escrow Watch: Wiseway founders free to sell almost half of company
News
Rise and Shine: What you need to know before the ASX opens
News
Lunchtime ASX small cap wrap: Who’s hitting the panic button today?
Health & Biotech
Health: UBI has more cash than its market cap
News
10 at 10: These ASX stocks are jumping ahead today
IPO Watch
IPO Watch: The average 2019 IPO is up 52 per cent
News
Busy August sees capital raised on the ASX grow by 93pc
IPO Watch